Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 03/16 05:35:06 pm
67.94 EUR   +0.50%
02/21Arix, Fosun in China-focused deal
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Aca..
01/31UCB : Transparency Notification
News SummaryMost relevantAll newsSector newsTweets

UCB : Acquisition of own shares in the framework of employees’ long-term incentive plans

share with twitter share with LinkedIn share with facebook
share via e-mail
08/04/2011 | 08:05pm CET

BRUSSELS, Belgium, 4 August 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 7,600 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:


Price EUR

















These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company’s share option plans of which the detail is given in UCB annual report.

UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608

For further information [email protected]

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

[email protected]

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712,

About UCB ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). www.ucb.com

UCB, Brussels, Belgium (

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on UCB
03/15UCB : Data on Cardiology Detailed by Researchers at UCB S.A. (miR-21-5p as a pot..
03/08UCB : Patent Issued for Systems and Methods for Administering Medication (USPTO ..
02/21Arix, Fosun in China-focused deal
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Academy &hellip..
02/08UCB : New Findings on Biomarkers Described by Investigators at UCB S.A. (Dampeni..
02/08UCB : Findings on Therapeutics Research Reported by Investigators at UCB S.A. (U..
01/31UCB : Transparency Notification
01/29UCB : Transparency Notification
01/19UCB S.A. REPORTS FINDINGS IN PARKINS : A randomized,...
01/12Pfizer's Barrett named CEO of Novartis Oncology
More news
News from SeekingAlpha
02/23UCB S.A. 2017 Q4 - Results - Earnings Call Slides 
02/22UCB S.A. reports FY results 
01/20YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O.. 
01/19Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket 
01/08EMA accepts UCB's marketing application for osteoporosis med romosozumab 
Financials (€)
Sales 2018 4 561 M
EBIT 2018 1 116 M
Net income 2018 774 M
Finance 2018 100 M
Yield 2018 1,82%
P/E ratio 2018 16,41
P/E ratio 2019 14,63
EV / Sales 2018 2,88x
EV / Sales 2019 2,66x
Capitalization 13 215 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 20
Average target price 68,6 €
Spread / Average Target 0,91%
EPS Revisions
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB2.66%16 234
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965